Comprehensive Stock Comparison
Compare Protagonist Therapeutics, Inc. (PTGX) vs Can-Fite BioPharma Ltd. (CANF) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CANF | -9.3% revenue growth vs PTGX's -100.0% |
| Stability / Safety | PTGX | Lower D/E ratio (1.7% vs 1.9%) |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CANF | +169.9% vs PTGX's +145.0% |
| Efficiency (ROA) | PTGX | -19.5% ROA vs CANF's -114.0%, ROIC -21.8% vs -448.3% |
Who Each Stock Is For
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based drugs for blood disorders and inflammatory diseases. It generates revenue primarily through collaboration agreements — notably with Janssen Biotech — and has no commercial products yet, relying on milestone payments and potential future royalties. The company's key advantage is its proprietary peptide discovery platform that enables the development of orally available peptide therapeutics, a challenging area in drug development.
Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule drugs targeting inflammatory diseases and cancer. It generates revenue primarily through licensing agreements and milestone payments from partners — with no commercial products yet — as it advances its lead candidates through clinical trials. The company's competitive advantage lies in its proprietary A3 adenosine receptor platform, which targets a novel pathway for treating autoimmune and inflammatory conditions.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
PTGX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). CANF leads in 1 (Financial Metrics). 2 tied.
Financial Metrics (TTM)
CANF and PTGX operate at a comparable scale, with $560,000 and $0 in trailing revenue. On growth, CANF holds the edge at -36.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PTGXProtagonist Thera… | CANFCan-Fite BioPharm… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $560,000 |
| EBITDAEarnings before interest/tax | -$158M | -$9M |
| Net IncomeAfter-tax profit | -$130M | -$9M |
| Free Cash FlowCash after capex | $58M | -$8M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -16.0% |
| Net MarginNet income ÷ Revenue | — | -15.7% |
| FCF MarginFCF ÷ Revenue | — | -14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -122.6% | -36.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -134.8% | +36.4% |
Valuation Metrics
| Metric | PTGXProtagonist Thera… | CANFCan-Fite BioPharm… |
|---|---|---|
| Market CapShares × price | $5.8B | $14.2B |
| Enterprise ValueMkt cap + debt − cash | $5.6B | $14.2B |
| Trailing P/EPrice ÷ TTM EPS | -44.92x | -4.40x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.45x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 9999.00x |
| Price / BookPrice ÷ Book value/share | 9.52x | 6.34x |
| Price / FCFMarket cap ÷ FCF | 99.91x | — |
Profitability & Efficiency
PTGX delivers a -21.2% return on equity — every $100 of shareholder capital generates $-21 in annual profit, vs $-2 for CANF. PTGX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to CANF's 0.02x. On the Piotroski fundamental quality scale (0–9), PTGX scores 4/9 vs CANF's 1/9, reflecting mixed financial health.
| Metric | PTGXProtagonist Thera… | CANFCan-Fite BioPharm… |
|---|---|---|
| ROE (TTM)Return on equity | -21.2% | -2.1% |
| ROA (TTM)Return on assets | -19.5% | -114.0% |
| ROICReturn on invested capital | -21.8% | -4.5% |
| ROCEReturn on capital employed | -24.0% | -108.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.02x | 0.02x |
| Net DebtTotal debt minus cash | -$118M | -$5M |
| Cash & Equiv.Liquid assets | $128M | $5M |
| Total DebtShort + long-term debt | $10M | $104,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -580.71x |
Total Returns (with DRIP)
A $10,000 investment in PTGX five years ago would be worth $34,422 today (with dividends reinvested), compared to $2,351 for CANF. Over the past 12 months, CANF leads with a +169.9% total return vs PTGX's +145.0%. The 3-year compound annual growth rate (CAGR) favors PTGX at 78.4% vs CANF's 20.6% — a key indicator of consistent wealth creation.
| Metric | PTGXProtagonist Thera… | CANFCan-Fite BioPharm… |
|---|---|---|
| YTD ReturnYear-to-date | +5.6% | +2059.1% |
| 1-Year ReturnPast 12 months | +145.0% | +169.9% |
| 3-Year ReturnCumulative with dividends | +467.7% | +75.3% |
| 5-Year ReturnCumulative with dividends | +244.2% | -76.5% |
| 10-Year ReturnCumulative with dividends | +687.0% | -98.5% |
| CAGR (3Y)Annualised 3-year return | +78.4% | +20.6% |
Risk & Volatility
PTGX is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than CANF's 0.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | PTGXProtagonist Thera… | CANFCan-Fite BioPharm… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.11x | 0.36x |
| 52-Week HighHighest price in past year | $96.54 | $4.93 |
| 52-Week LowLowest price in past year | $35.97 | $0.17 |
| % of 52W HighCurrent price vs 52-week peak | +95.4% | +96.3% |
| RSI (14)Momentum oscillator 0–100 | 62.7 | 68.6 |
| Avg Volume (50D)Average daily shares traded | 594K | 4.3M |
Analyst Outlook
Wall Street rates PTGX as "Buy" and CANF as "Buy". Consensus price targets imply 52.6% upside for CANF (target: $7) vs 21.4% for PTGX (target: $112).
| Metric | PTGXProtagonist Thera… | CANFCan-Fite BioPharm… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $111.75 | $7.25 |
| # AnalystsCovering analysts | 24 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 20 | Feb 26 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | 100 | 1,064.74 | +964.7% |
| Can-Fite BioPharma … (CANF) | 100 | 33.04 | -67.0% |
Protagonist Therape… (PTGX) returned +244% over 5 years vs Can-Fite BioPharma … (CANF)'s -76%. A $10,000 investment in PTGX 5 years ago would be worth $34,422 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | $0.00 | $0.00 | — |
| Can-Fite BioPharma … (CANF) | $169500.00 | $674000.00 | +297.6% |
Protagonist Therapeutics, Inc.'s revenue grew from $0M (2016) to $0M (2025) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | -184.2% | 63.3% | +134.4% |
| Can-Fite BioPharma … (CANF) | -29.1% | -11.7% | +59.9% |
Can-Fite BioPharma Ltd.'s net margin went from -29% (2015) to -12% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Protagonist Therape… (PTGX) | -5.72 | -2.05 | +64.2% |
| Can-Fite BioPharma … (CANF) | -90 | -1.08 | +98.8% |
Protagonist Therapeutics, Inc.'s EPS grew from $-5.72 (2016) to $-2.05 (2025).
Chart 5Free Cash Flow — 5 Years
Protagonist Therapeutics, Inc. generated $58M FCF in 2025 (+153% vs 2021). Can-Fite BioPharma Ltd. generated $-8M FCF in 2024 (+23% vs 2021).
PTGX vs CANF: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PTGX or CANF a better buy right now?
Analysts rate Protagonist Therapeutics, Inc. (PTGX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PTGX or CANF?
Over the past 5 years, Protagonist Therapeutics, Inc. (PTGX) delivered a total return of +244.2%, compared to -76.5% for Can-Fite BioPharma Ltd. (CANF). A $10,000 investment in PTGX five years ago would be worth approximately $34K today (assuming dividends reinvested). Over 10 years, the gap is even starker: PTGX returned +687.0% versus CANF's -98.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PTGX or CANF?
By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc. (PTGX) is the lower-risk stock at -0.11β versus Can-Fite BioPharma Ltd.'s 0.36β — meaning CANF is approximately -430% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 2% for Can-Fite BioPharma Ltd. — giving it more financial flexibility in a downturn.
04Which has better profit margins — PTGX or CANF?
Protagonist Therapeutics, Inc. (PTGX) is the more profitable company, earning 0.0% net margin versus -1169.1% for Can-Fite BioPharma Ltd. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTGX leads at 0.0% versus -1206.2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is PTGX or CANF more undervalued right now?
Analyst consensus price targets imply the most upside for CANF: 52.6% to $7.25.
06Which pays a better dividend — PTGX or CANF?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PTGX or CANF better for a retirement portfolio?
For long-horizon retirement investors, Protagonist Therapeutics, Inc. (PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.11), +687.0% 10Y return). Both have compounded well over 10 years (PTGX: +687.0%, CANF: -98.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PTGX and CANF?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.